OncoSec Medical Inc. announced today the appointment of Sara Bonstein as chief financial officer and chief operating officer.
In her new roles Bonstein will lead financial and capital market activity and oversee G&A and technical operations for the biotechnology company which moved its executive offices from San Diego, California to Pennington in May. She succeeds former Chief Financial Officer Richard Slansky, who is leaving to pursue new opportunities.
Bonstein comes to the position with a comprehensive background providing leadership at biotech companies. Most recently she served as chief financial officer, secretary, treasurer and executive vice president at Advaxis, and previously held key financial positions at Eli Lilly & Co., ImClone Systems and Johnson & Johnson.
“Sara is a seasoned strategic executive with significant experience in the public biotechnology and pharmaceutical industry,” said OncoSec President and CEO Daniel O’Connor. “She joins OncoSec at an extremely important time, as we look to achieve several key milestones in the remainder of 2018. Sara has a proven track record of success … “
While with Advaxis, Bonstein was honored as an NJBIZ CFO of the Year award winner for health care in 2016.